InsiderTrades.com logo
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research   |   Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.
Tito Serafini net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Tito Serafini Biography and Net Worth

Insider of Atreca
Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.

What is Tito Serafini's net worth?

The estimated net worth of Tito Serafini is at least $6,553.53 as of August 2nd, 2023. Dr. Serafini owns 72,817 shares of Atreca stock worth more than $6,554 as of December 24th. This net worth evaluation does not reflect any other investments that Dr. Serafini may own. Additionally, Dr. Serafini receives a salary of $665,500.00 as Insider at Atreca. Learn More about Tito Serafini's net worth.

How old is Tito Serafini?

Dr. Serafini is currently 61 years old. There are 3 older executives and no younger executives at Atreca. Learn More on Tito Serafini's age.

What is Tito Serafini's salary?

As the Insider of Atreca, Inc., Dr. Serafini earns $665,500.00 per year. The highest earning executive at Atreca is Mr. John A. Orwin M.B.A., President, CEO, Director & Principal Financial Officer, who commands a salary of $927,030.00 per year. Learn More on Tito Serafini's salary.

How do I contact Tito Serafini?

The corporate mailing address for Dr. Serafini and other Atreca executives is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. Atreca can also be reached via phone at (650) 595-2595 and via email at [email protected]. Learn More on Tito Serafini's contact information.

Has Tito Serafini been buying or selling shares of Atreca?

Tito Serafini has not been actively trading shares of Atreca during the last ninety days. Most recently, Tito Serafini sold 5,487 shares of the business's stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $0.95, for a transaction totalling $5,212.65. Following the completion of the sale, the insider now directly owns 72,817 shares of the company's stock, valued at $69,176.15. Learn More on Tito Serafini's trading history.

Who are Atreca's active insiders?

Atreca's insider roster includes Norman Greenberg (Insider), William Robinson (Director), and Tito Serafini (Insider). Learn More on Atreca's active insiders.

Tito Serafini Insider Trading History at Atreca

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2023Sell5,487$0.95$5,212.6572,817View SEC Filing Icon  
9/2/2022Sell7,646$1.78$13,609.8834,554View SEC Filing Icon  
6/28/2022Sell15,000$2.02$30,300.00228,875View SEC Filing Icon  
3/4/2022Sell30,000$5.00$150,000.00View SEC Filing Icon  
9/27/2021Sell30,000$6.58$197,400.00View SEC Filing Icon  
3/11/2021Sell10,000$18.31$183,100.00View SEC Filing Icon  
2/11/2021Sell10,000$18.93$189,300.00View SEC Filing Icon  
1/11/2021Sell10,000$15.02$150,200.00View SEC Filing Icon  
12/11/2020Sell10,000$15.87$158,700.00View SEC Filing Icon  
11/16/2020Sell8,847$15.12$133,766.64View SEC Filing Icon  
10/12/2020Sell10,000$15.00$150,000.003,655View SEC Filing Icon  
10/6/2020Sell1,218$15.05$18,330.903,655View SEC Filing Icon  
9/18/2020Sell8,782$15.11$132,696.023,655View SEC Filing Icon  
8/14/2020Sell10,000$15.00$150,000.003,655View SEC Filing Icon  
7/13/2020Sell10,000$20.20$202,000.003,655View SEC Filing Icon  
6/25/2020Sell600$25.01$15,006.003,655View SEC Filing Icon  
6/22/2020Sell496$20.05$9,944.803,655View SEC Filing Icon  
6/19/2020Sell4,604$20.03$92,218.123,655View SEC Filing Icon  
6/11/2020Sell10,000$17.44$174,400.003,655View SEC Filing Icon  
5/26/2020Sell200$20.00$4,000.003,655View SEC Filing Icon  
5/11/2020Sell10,000$18.00$180,000.003,655View SEC Filing Icon  
4/16/2020Sell10,000$16.28$162,800.003,655View SEC Filing Icon  
See Full Table

Tito Serafini Buying and Selling Activity at Atreca

This chart shows Tito Serafini's buying and selling at Atreca by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atreca Company Overview

Atreca logo
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Read More

Today's Range

Now: $0.09
Low: $0.09
High: $0.09

50 Day Range

MA: $0.09
Low: $0.09
High: $0.09

2 Week Range

Now: $0.09
Low: $0.05
High: $1.20

Volume

N/A

Average Volume

4,609,200 shs

Market Capitalization

$3.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
From Brownstone Research   |   Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.